Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891436 · ClinicalTrials.gov registry record · Phase 4
Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms
A Phase 4 study of Allergic Conjunctivitis to Tree Pollen or Grass Pollen, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00891436: Completed Phase 4 study of Allergic Conjunctivitis to Tree Pollen or Grass Pollen, sponsored by Rush University Medical Center.
NCT00891436 is a Phase 4 study of Allergic Conjunctivitis to Tree Pollen or Grass Pollen that has completed, run by Rush University Medical Center. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00891436, a Phase 4 study of Allergic Conjunctivitis to Tree Pollen or Grass Pollen, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Rationale and objectives: Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively treat ocular symptoms, the mechanism has not been delineated. Furthermore, the tears of patients with allergic conjunctivitis are known to have increased concentrations of cytokines and allergic mediators. The objective of this study is to determine if the positive effects of Veramyst nasal spray on ocular symptoms is via the inhibition of allergic mediators in the eyes. The investigators will conduct a double blind placebo controlled trial to determine if Veramyst nasal spray decreases the amount of allergic mediators in the tears of subjects randomized to Veramyst nasal spray versus placebo. The investigators will also compare the subjects' symptoms to the amount of allergic mediators detected in their tears.
Primary Outcome
Tear samples from the participants eyes were collect and were to be used for measuring esinophilic cationic prtein, but this was not measured because the volume of tears were to low.
Conditions Studied
Interventions
- DRUG Placebo nasal spray
- DRUG Fluticasone furoate nasal spray
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
What the finished NCT00891436 record still lists
NCT00891436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Allergic Conjunctivitis to Tree Pollen or Grass Pollen appearing as the primary indexed condition, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT00891436 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00891436 about?
NCT00891436 is a clinical study titled "Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms". Rationale and objectives: Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively ...
What is the current status of trial NCT00891436?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2009-04. Estimated completion is 2009-08.
What conditions does trial NCT00891436 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis to Tree Pollen or Grass Pollen.
What interventions are being tested in trial NCT00891436?
The interventions under investigation include: Placebo nasal spray (DRUG), Fluticasone furoate nasal spray (DRUG).
Who is sponsoring clinical trial NCT00891436?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00891436 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00891436's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia